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Abstract
Background: A cardio-ankle vascular index (CAVI) has been developed to represent the extent of arteriosclerosis
throughout the aorta, femoral artery and tibial artery independent of blood pressure. To practically use CAVI as a
diagnostic tool for determining the extent of arteriosclerosis, our study objectives were (1) to establish the baseline
CAVI scores by age and gender among cardiovascular disease (CVD) risk-free persons, (2) to compare CAVI scores
between genders to test the hypothesis that the extent of arteriosclerosis in men is greater than in women, and
(3) to compare CAVI scores between the CVD risk-free group and the CVD high-risk group in order to test the
hypothesis that the extent of arteriosclerosis in the CVD high-risk group is greater than in the CVD risk-free group.
Methods: Study subjects were 32,627 urban residents 20-74 years of age who participated in CVD screening in
Japan during 2004-2006. A new device (model VaSera VS-1000) was used to measure CAVI scores. At the time of
screening, CVD high-risk persons were defined as those having any clinical abnormalities of CVD, and CVD risk-free
persons were defined as those without any clinical abnormalities of CVD. Age-specific average CAVI scores were
compared between genders and between the CVD risk-free group and the CVD high-risk group. Student’s t-test
using two independent samples was applied to a comparison of means between two groups.
Results: Average age-specific baseline scores of CAVI in the CVD risk-free group linearly increased in both genders
as their age increased. Average age-specific baseline scores of CAVI in the CVD risk-free group were significantly
greater among men than among women. Average age-specific baseline scores of CAVI in the CVD risk-free group
were significantly smaller than those in the CVD high-risk group in both genders after 40 years of age.
Conclusions: The baseline CAVI scores from the CVD risk-free group are useful for future studies as control values.
The CAVI method is a useful tool to screen persons with moderate to advanced levels of arteriosclerosis.
Background
One leading cause of premature deaths in industrialized
nations is cardiovascular disease including coronary
heart disease (CHD), an atherosclerosis-related disease.
In 2005, the CHD death rates (per 100,000 persons)
were 159.0 for US males, which was 2.3 times higher
than for Japanese males (68.1), and 142.0 for US
females, which was 2.7 times higher than for Japanese
females (53.5) [1,2]. Thus, there is a great need to pre-
vent CHD incidence as well as mortality in the US. One
approach is to identify persons with moderately
advanced state of arteriosclerosis and provide recom-
mendations for improving their lifestyle and diet. Japan
has been taking such an approach for the past few dec-
ades and successfully kept CHD mortality low [2].
One method to quantitatively estimate the extent of
arteriosclerosis is the use of the pulse wave velocity
(PWV). The idea on the association of PWV with arter-
iosclerosis is traced back to an experiment using artifi-
cial blood vessels conducted by Moens in 1878 [3].
Then, Bramwell and colleagues showed that PWV
depends on the modulus of arterial volume elasticity by
experiments in 1922-23 [3-7]. Their experimental results
have been a basis for the development of the measure-
ment device PWV-200 (Fukuda-Denshi Co., Tokyo)
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(thorax, abdomen, and part of common iliac artery)
from the aortic valve to the femoral pulsation point, as
described by Hasegawa in 1970 [8]. Because PWV is
highly correlated with diastolic blood pressure, Hase-
gawa developed a nomogram showing the association
between diastolic blood pressure and PWV. He pro-
posed an adjustment to any measured PWV values at 80
mmHg. As a result, such an adjustment was built into
the PWV-200 machine. This is an important step allow-
ing clinicians and researchers to compare PWV values
between individuals and between populations. Namekata
et al. conducted cardiovascular disease prevention
screening in Seattle and found that PWV was positively
and significantly associated with aging (≥ 60 years of
age), hypertension, diabetes, the ratio of total cholesterol
to high density lipoprotein cholesterol, ex-smokers and
negatively and significantly with alcohol consumption
among Japanese Americans [9]. In addition, they had
similar findings among Japanese urban workers [10].
To overcome some problems associated with PWV-
200 (i.e., technical difficulty in the method for measur-
ing PWV), the cardio-ankle vascular index (CAVI) was
developed as a new indicator of arteriosclerosis in
2004 [11]. CAVI quantitatively reflects arteriosclerosis
of the aorta, femoral and tibial arteries based on Bram-
well-Hill’s equation [3] and stiffness parameter [12]
which is allowed to be converted from PWV propagat-
ing from the aortic valve to ankle. Some researchers
proposed to use CAVI scores as an indicator of athero-
sclerosis. Nakamura et al. found a strong association of
C A V Iw i t ht h ep r e s e n c eo fs e v e r i t yo fc o r o n a r ya t h e r o -
sclerosis based on their ordinal logistic regression ana-
lysis [13]. Kadota et al. suggested the use of CAVI as a
screening tool for atherosclerosis based on their find-
ings from the general population study of 1,014 adults
showing strong significant associations of CAVI scores
with carotid intima-media thickness and with homo-
cysteine after adjustment for age and sex [14]. Thus, it
is considered that CAVI scores reflect arterial stiffness,
atherosclerosis and arteriosclerosis of which conditions
are overlapping and inseparable. We use CAVI
to represent the extent of arteriosclerosis in this paper
but it is inclusive of arterial stiffness and
atherosclerosis.
To practically use CAVI as a diagnostic tool for deter-
mining the extent of arteriosclerosis, our study objec-
tives are (1) to establish the baseline CAVI scores by
age and gender among cardiovascular disease (CVD)
risk-free persons, (2) to compare CAVI scores between
genders to test the hypothesis that the extent of arterio-
s c l e r o s i si nm e ni sg r e a t e rt h a ni nw o m e n ,a n d( 3 )t o
compare CAVI scores between the CVD risk-free group
and the CVD high-risk group to test the hypothesis that
the extent of arteriosclerosis in the CVD high-risk
group is greater than in the CVD risk-free group.
Methods
Study Subjects
Subjects for the study were recruited through the
screening program at Japan Health Promotion Founda-
tion which has been conducting cardiovascular disease
and cancer screening throughout major cities of Japan.
Subjects were company employees and their family
members: 16,661 men and 15,966 women between 20
and 74 years of age (see Table 1) after excluding persons
with history of heart disease, hypertension, stroke, dia-
betes, nephritis, and gout. The proportion of CVD risk-
free subjects to all subjects decreases as age advances
(both genders combined): 45.4% for 20-29 years of age,
30.1% for 30-39 years of age, 18.7% for 40-49 years of
age, 9.7% for 50-59 years of age, 6.9% for 60-69 years of
age, and 3.7% (or only 36 CVD risk-free subjects out of
979 subjects) for 70-74 years of age.
The study was approved by the Institutional Review
Board and all subjects gave their consent to participate
in the study.
Measuring Cardio-Ankle Vascular Index
CAVI, a stiffness and arteriosclerosis indicator of thorax,
abdomen, common iliac, femoral and tibial arteries, is
measured by VaSera VS-1000 manufactured by Fukuda-
Denshi Company, LTD (Tokyo, Japan), as shown in Figure
1. This device is a new version of PWV-200. It is signifi-
cantly improved as it achieved 3.8% of the average coeffi-
cient of variation among five repeated measurements of
CAVI for each of the 22 subjects [11] showing that its
operation is less dependent on a technician’ss k i l l .F u r t h e r -
more, CAVI scores were not changed but brachial-ankle
PWV values were significantly changed when both systolic
and diastolic blood pressure of 12 healthy volunteer men
was significantly changed after metoprolol (80 mg) was
administered [15]. This suggests that CAVI is not affected
by blood pressure at the time of measuring.
The method to measure CAVI is illustrated in Figure
2. A subject is placed in supine position and
Table 1 Subjects by age and sex
All subjects CVD risk-free subjects
Age Males Females Males Females
20-29 1214 949 455 526
30-39 4008 3243 877 1307
40-49 3880 4111 421 1077
50-59 4619 5653 306 690
60-69 2319 1654 155 119
70-74 623 356 25 11
Total 16661 15966 2239 3730
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Page 2 of 10electrocardiogram and heart sound are monitored. PWV
between heart and ankle is obtained by L/T where L is
the distance from the aortic valve to the ankle, and T is
the time during which PWV propagates from the aortic
valve to the ankle (or the sum of tb and tba in place of
t’b and tba, because t’b and tb are theoretically equal:
tba is the time between the rise of the brachial pulse
wave and the rise of the ankle pulse wave, tb is the time
between the aortic valve’s closing sound and the notch
of the brachial pulse wave, and t’b is the time between
the aortic valve’s opening sound and the rise of the bra-
chial pulse wave) [11].
The scale conversion from PWV to CAVI is per-
formed by the following formula:
CAVI = a

2ρ/ P

× ln

Ps/Pd

PWV2
+b
where Ps and Pd are systolic and diastolic blood pres-
sure values, respectively, PWV is the pulse wave velocity
between heart and ankle, ΔPi sP s-Pd, r is blood density,
and a and b are constants. This equation was derived
from Bramwell-Hill’s equation [3] and stiffness para-
meter [12]. Scale conversion constants are determined
so as to match CAVI with PWV by Hasegawa’s method
[8]. All these measurements and calculations are auto-
matically made in VaSera VS-1000. More theoretical
details of CAVI method are available elsewhere [11].
Clinical Criteria for Selecting CVD Risk-Free Persons and
CVD High-Risk Persons
Blood was drawn from the subjects after a 12 hour-fast.
The following measurements were made: total cholesterol
(TC), triglycerides (TG), creatinine (Cre) by enzymatic
Figure 1 Demonstration of CAVI measurement by VaSera VS-1000.
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modified enzymatic method; uric acid by uricase peroxides
method, glucose by hexokinase glucose-6-phosphate dehy-
drogenate assay, glyco-hemoglobin A1c (HbA1c) by latex
agglutination, and white blood cells (WBC) by direct cur-
rent detection method. To identify subjects with ischemic
changes, outputs from electrocardiogram were classified
by Minnesota code [16] which has been internationally
and uniformly used in the epidemiology setting. Retinal
photographs of the right eye were taken by non-mydriatic
retinal camera (Canon Co., Tokyo, Japan) to identify sub-
jects with abnormal changes in retinal arteries by using
Scheie’s classification method [17].
The criteria to select subjects for the CVD risk-free
group and for the CVD high-risk group were based on
the guidelines established by Japan Atherosclerosis
Society and Japan Society of Hypertension [18-21]. The
CVD risk-free persons were defined as those meeting
the following clinical criteria at the time of screening:
￿ blood pressure: systolic blood pressure(SBP) ≤ 139
mmHg and diastolic blood pressure (DBP) ≤ 89
mmHg;
￿ serum lipids: TC ≤ 219 mg/dL, HDL-C = 40-99
mg/dL and TG ≤ 149 mg/dL;
￿ serum glucose: glucose ≤ 109 mg/dL and HbA1c ≤
5.8%;
￿ renal function: creatinine: male ≤ 1.10 mg/dL,
female ≤ 0.80 mg/dL and uric-acid ≤ 7.0 mg/dL for
both genders;
￿ white blood cells: 3.2-8.5 × 10
3/μL;
￿ electrocardiogram: excluding persons with 1-1-1 to1-
3-6, 3-1 to 3-3, 4-1 to 4-4, 5-1 to 5-5, and 9-2; and
￿ retinal artery changes: no arteriolar sclerotic
change and no hypertensive change.
The CVD high-risk persons were defined as those who
fall in one or more following groups of clinical abnorm-
alities at the time of screening:
￿ borderline hypertension group: SBP:140-159
mmHg, and/or DBP:90-99 mmHg;
￿ hypertension group: SBP ≥ 160 mmHg, and/or
DBP ≥ 100 mmHg;
￿ abnormal lipid metabolism group: TC ≥ 240 mg/
dL, TG ≥ 250 mg/dL, and/or HDL-C ≤ 34 mg/dL;
Figure 2 Illustration of CAVI measurement.
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Page 4 of 10￿ borderline high-glucose group: serum glucose 110-
125 mg/dL and/or HbA1c 5.9-6.1%;
￿ hyperglycemia group: serum glucose ≥ 126 mg/dL
and/or HbA1c ≥ 6.2%;
￿ ischemic change group: 1-1-1 to 1-1-3 (abnormal
Q wave), and/or 4-1 to 4-3 (ischemic change); and
￿ arteriolar sclerotic change group: sclerotic change
≥ II in Scheie’s method.
Statistics Methods
In addition to the use of descriptive statistics, Student’s
t-test using two independent samples was applied to a
comparison of means between two groups and p < 0.05
was considered statistically significant. Statistical
Packages for Social Sciences version 16 was used for
data analysis.
Results
A ss h o w ni nT a b l e1 ,t h e r ew e r e2 , 2 3 9m e na n d3 , 7 3 0
women who were free from clinical CVD abnormalities.
Table 2 represents age-specific means and standard
deviations of the baseline CAVI scores from the CVD
risk-free group by age and gender. Age-specific average
CAVI scores became higher in both genders as their age
advanced and 0.22-0.66 of increment was added to the
average CAVI score as the age increased to every 10
years.
Figure 3 shows a comparison of age-specific average
CAVI scores between genders. It is observed that aver-
age CAVI scores at each age-interval were significantly
greater for men than for women with a borderline sig-
nificance for 70-74 years of age (p = 0.071), and that
men’s CAVI scores were about 5 years ahead of
women’s between 30 and 60 years of age and even 10
years ahead of women’s after 60 years of age.
Tables 3 and 4 show a comparison of average CAVI
scores between the CVD risk-free group and each CVD
high-risk group by age among men and among women,
respectively. There were not enough cases of all CVD
high-risk groups under 30 years of age for comparisons
a n do fs o m eC V Dh i g h - r i s kg r o u p s3 0 - 3 9y e a r so fa g e .
Most average CAVI scores from each of the CVD high-
risk groups were significantly higher than those from
the CVD risk-free groups with one exception: the aver-
age CAVI score (6.95) of the hypercholesterolemia and
hypertriglyceridemia group for men 30-39 years of age
was significantly smaller than that (7.12) of the CVD
risk-free group for the same gender and age-bracket (p
= 0.021). On one hand, age-specific average CAVI
scores of the hypertension group were significantly
greater than those of the CVD risk-free group after 30
years of age among men but after 40 years of age
among women. On the other hand, age-specific average
CAVI scores of the hypercholesterolemia and hypertri-
glyceridemia group, the hyperglycemia group, the
ischemic changes group, and the retinal artery changes
group were significantly greater for both men and
women after 40 years of age compared to those of the
CVD risk-free group with exceptions of non-significance
in the hypercholesterolemia and hypertriglyceridemia
group of men 70-74 years of age (p = 0.106), in the
hyperglycemia group of women 40-49 years of age (p =
0.093), and in the ischemic changes group and the ret-
inal artery changes group of women 70-74 years of age
(p = 0.052 and p = 0.071, respectively).
Figures 4 and 5 show differences in average CAVI
scores by age between the CVD risk-free group and all
CVD high-risk groups combined for men and for
women, respectively. After 40 years of age, the differ-
ence in age-specific average CAVI scores became statis-
tically significant between the two groups, with
borderline significance in men 70-74 years of age (p =
0.054), and also became wider as age advanced both for
men and for women.
Discussion
As shown in Table 2, we have established the baseline
CAVI scores based on 5,969 CVD risk-free persons
selected out of 32,627 persons 20-74 years of age. It is
shown that there exists a linear association between
CAVI scores and age in both genders confirming that
aging is an independent risk factor of atherosclerosis
and cardiovascular disease as described in western
[22,23] and Japanese studies [24]. Table 2 and Figure 3
show a biological aging of major arteries among CVD
risk-free persons. We found that age-specific average
CAVI scores among men were significantly greater than
among women. Such a finding is consistent with the
fact that men have a higher risk for coronary heart dis-
ease (of which one major risk factor is arteriosclerosis)
than women [1,2]. Based on these findings, we need to
evaluate an individual’s CAVI scores according to his/
her age and gender when we conduct screening.
Table 2 Comparison of average cardio-ankle vascular
index (CAVI) scores of CVD risk-free subjects by age and
gender
Males Females t-value p-value
Age Mean SD Mean SD
20-29 6.69 0.70 6.57 0.66 2.89 p = 0.005
30-39 7.12 0.68 6.79 0.63 5.23 p < 0.001
40-49 7.59 0.70 7.29 0.66 7.82 p < 0.001
50-59 8.07 0.76 7.82 0.70 4.97 p < 0.001
60-69 8.73 0.81 8.26 0.72 4.95 p < 0.001
70-74 9.35 1.00 8.71 0.75 1.88 p = 0.071
Note: SD indicates standard deviation.
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[25-27], hypertension is a risk factor of cardiovascular
disease. Hypertension is also significantly associated
with PWV [9,10,28]. High PWV values are found to be
an independent predictive factor of cardiovascular dis-
ease [29]. Since our results indicate that age-specific
average CAVI scores in the hypertension group were
significantly higher than those from the CVD risk-free
group (Tables 3, 4), it is implied that hypertension is a
risk factor of arteriosclerosis.
The association between serum lipid levels and ather-
osclerotic disease, namely coronary heart disease, has
been established through the findings from several epi-
demiological studies such as the Seven Countries Study
[30], the Multiple Risk Factor Intervention Trial Study
[31], and Klag et al’s follow-up study [32]. Namekata et
al. reported that abnormally high PWV was significantly
associated with 4.5 or greater value of the ratio of total
cholesterol to high density lipoprotein (HDL) choles-
terol implying that abnormal lipid imbalance is a risk
factor of arterial stiffness and arteriosclerosis [9]. Our
results support such an association by showing that
age-specific average CAVI scores among persons with
hypercholesterolemia and hypertriglyceridemia of ages
40 and over were significantly greater than those among
CVD risk-free persons for the same age-specific groups
(Tables 3, 4).
Diabetes mellitus is proven to be a risk factor for car-
diovascular disease [33,34]. It is reported that CVD risk
among diabetics was 2-6 times higher than among non-
diabetics and PWV values were associated with fasting
glucose levels among diabetics [35,36]. An odds ratio for
having abnormally high PWV among diabetics is also
reported to be 3.66 (p < 0.001) as compared to non-dia-
betics [9]. Our results are consistent with these findings
by showing significantly higher average age-specific
CAVI scores among persons with hyperglycemia after
40 years of age than those among CVD risk-free persons
(Tables 3, 4).
Ischemic changes in ECG and arteriolar changes in
retina are considered as surrogate markers of arterial
stiffness and arteriosclerosis in the coronary arteries and
retinal arteries, respectively. It is also shown that athero-
sclerotic lesions in the aorta proceeds onset of CVD
[37-39], as an increase in PWV values proceeds ischemic
changes in ECG and arterial changes in retina appear
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Figure 3 Differences in average CAVI scores by age between males (blue line) and females (green line) among CVD risk-free
individuals based on results shown in Table 2 (Vertical bars indicate standard deviation.).
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scores of the ischemic changes group and of the retinal
artery changes group were significantly greater than
those of the CVD risk-free group (Tables 3, 4). This
implies that CAVI scores reflect the extent of arterio-
sclerotic changes not only in medium-size and large-size
arteries but also in small-size arteries.
We have shown that age-specific average CAVI scores
of all CVD high-risk persons combined were signifi-
cantly higher than those of the CVD risk-free group
after 40 years of age (Tables 3, 4), indicating that the
overall arteriosclerosis status of the CVD high-risk
group was significantly worse than that of the CVD
risk-free group. Because no difference in average CAVI
scores between the two groups was detected before 40
years of age, effective CAVI screening might be recom-
mended for people age 40 and over.
With regard to the validity to use CAVI scores as an
indicator of arteriosclerosis, Otsuka examined 72
deceased patients’ ante-mortem PWV (which is a basis
for deriving CAVI scores) and pathological changes
measured by the diffuse fibrotic thickening, formation of
atheroma and calcification in the wall of their aorta. He
reported multiple regression coefficient R = 0.810
between PWV and scores of those pathological changes
[41]. In addition, other researchers reported that CAVI
scores were significantly associated with coronary
Table 3 Comparison of average CAVI scores between
CVD risk-free group and CVD high-risk groups for males
Age 20-29 30-39 40-49 50-59 60-69 70-75
CVD risk-free group
Mean 6.69 7.12 7.59 8.06 8.73 9.35
SD 0.70 0.68 0.70 0.76 0.81 1.00
Hypertension group
Mean - 7.43 7.86 8.47 9.12 9.84
SD 0.86 0.87 1.01 1.12 1.15
t-value 4.24 4.75 6.51 4.06 2.07
p-value p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.041
Hypercholesterolemia & Hypertriglyceridemia group
Mean - 6.95 7.74 8.42 8.97 9.71
SD 0.84 0.86 0.95 0.91 0.82
t-value -2.39 2.33 5.05 2.34 1.62
p-value p = 0.021 p = 0.023 p < 0.001 p = 0.022 P = 0.106
Hyperglycemia group
Mean - 7.25 7.76 8.68 9.41 10.01
SD 0.88 0.82 0.98 1.65 1.40
t-value 1.14 2.31 8.80 6.94 2.19
p-value p = 0.123 p = 0.034 p < 0.001 p < 0.001 p = 0.042
Ischemic changes group
Mean - - 7.81 8.79 9.29 9.97
SD 0.70 1.12 0.87 1.31
t-value 2.29 8.36 5.43 2.14
p-value p = 0.033 p < 0.001 p < 0.001 p = 0.043
Retinal artery changes group
Mean - - 8.09 8.77 9.16 9.97
SD 0.77 1.25 1.10 1.14
t-value 2.60 6.69 3.77 2.38
p-value p = 0.014 p < 0.001 p < 0.001 p = 0.022
All high-risk groups combined
Mean 6.39 7.18 7.79 8.49 9.12 9.80
SD 0.69 0.85 0.85 0.98 1.05 1.14
t-value -1.87 1.26 3.96 7.20 4.48 1.93
p-value p =
0.061
p = 0.209 p < 0.001 p < 0.001 p < 0.001 p = 0.054
Note: SD is standard deviation and - indicates that the number of cases was
too small to obtain any meaningful results.
Table 4 Comparison of average CAVI scores between
CVD risk-free group and CVD high-risk groups for
females
Age 20-29 30-39 40-49 50-59 60-69 70-75
CVD risk-free group
Mean 6.57 6.97 7.29 7.82 8.26 8.71
SD 0.66 0.63 0.66 0.70 0.72 0.74
Hypertension group
Mean - 7.02 7.73 8.16 8.89 9.46
SD 0.74 1.02 0.84 0.96 1.02
t-value 0.40 6.85 8.22 6.44 2.38
p-value p = 0.346 p < 0.001 p < 0.001 p < 0.001 p = 0.023
Hypercholesterolemia & Hypertriglyceridemia group
Mean - 6.97 7.68 8.00 8.77 9.26
SD 0.78 1.21 0.78 0.90 0.74
t-value -0.03 4.12 3.82 5.06 2.28
p-value p = 0.914 p < 0.001 p < 0.001 p < 0.001 p = 0.034
Hyperglycemia group
Mean - - 7.47 8.16 9.09 9.77
SD 0.86 0.74 1.04 0.79
t-value 1.74 5.23 6.57 3.69
p-value p = 0.093 p < 0.001 p < 0.001 p < 0.001
Ischemic changes group
Mean - - 7.49 8.10 8.75 9.39
SD 0.82 0.82 0.88 1.02
t-value 2.95 5.71 4.69 2.07
p-value p = 0.004 p < 0.001 p < 0.001 p = 0.052
Retinal artery changes group
Mean - - 8.03 8.34 9.36 9.32
SD 0.89 0.86 1.11 0.87
t-value 3.97 5.24 7.37 1.92
p-value p < 0.001 p < 0.001 p < 0.001 p = 0.071
All high-risk groups combined
Mean 6.88 6.93 7.58 8.12 8.81 9.34
SD 0.42 0.76 0.91 0.81 0.96 0.99
t-value 1.48 -0.56 6.25 8.05 5.96 2.09
p-value p =
0.138
p = 0.578 p < 0.001 p < 0.001 p < 0.001 p = 0.038
Note: SD is standard deviation and - indicates that the number of cases was
too small to obtain any meaningful results.
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Page 7 of 10atherosclerosis [13], with carotid intima-media thickness
and with homocysteine [14]. Thus, the use of CAVI
scores derived from PWV values is valid to estimate the
extent of arteriosclerosis.
VaSera VS-1000, which was used in our study, was
designed to measure CAVI scores independent of blood
pressure and CAVI scores represent the extent of arter-
iosclerosis between the aortic valve and the ankle. We
have shown biological aging of the major artery by mea-
suring CAVI scores in the CVD risk-free group and dis-
ease-related pathological aging of the major artery in the
CVD high-risk group. CAVI scores allow us to evaluate
the extent of arteriosclerosis in the major arteries
between the aortic valve and the ankle, to screen per-
sons with subclinical stage of CVD, and provide an
opportunity to modify diet and lifestyle to improve
CAVI scores as reported by Satoh et al [42]. Thus, the
use of CAVI scores potentially leads to savings on high
treatment costs and to prolonging many productive
lives.
There are some limitations in our study. First, the
study design was cross-sectional and results were based
on our observations at the time of screening. Secondly,
our data did not include behavioral and lifestyle factors,
although we consider that effects of such factors were
reflected on clinical measurements related to CVD
w h i c hw ei n c l u d e d .C u r r e n t l yw ea r ee x a m i n i n gt h e
association between CAVI scores and lifestyle factors
such as smoking, alcohol consumption, and body mass
index, and will report results in the near future.
Conclusions
Our results imply that advancement of arteriosclerosis
among men is greater in every age group than among
                   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Figure 4 Differences in average CAVI scores by age between the CVD risk-free group (blue line) and the CVD high-risk group (green
line) for males based on results shown in Table 3 (Vertical bars indicate standard deviation.)
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Page 8 of 10women. It is also implied that arteriosclerosis of the
CVD high-risk group advances faster than that of the
CVD risk-free group after 40 years of age. The baseline
CAVI scores from the CVD risk-free group are useful
for future studies as control values. The CAVI method
is a useful tool to screen persons with moderate to
advanced levels of arteriosclerosis.
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